Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous CRISPR-Cas9 engineered regnase-1/SOCS1 dual-edited tumor infiltrating lymphocytes KSQ-004EX

A preparation of autologous tumor infiltrating lymphocytes (TILs) gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to inactivate both the endogenous genes suppressor of cytokine signaling 1 (SOCS1) and Regnase-1, with potential immunomodulating and antineoplastic activities. Upon infusion of the autologous CRISPR-Cas9 engineered Regnase-1/SOCS1 dual-edited TILs KSQ-004EX back into the patient, the cells specifically recognize, target and kill the patient's tumor cells. Inactivation of endogenous SOCS1 and Regnase-1 in the TILs increases responsiveness to cytokine signals, increases persistence and memory formation of TILs, and enhances anti-tumor responses.
Synonym:autologous CRISPR-Cas9 engineered TILs KSQ-004EX
autologous dual-edit eTILs KSQ-004EX
autologous engineered tumor infiltrating lymphocytes KSQ-004EX
autologous eTILs KSQ-004EX
autologous SOCS1/regnase-1 inactivated engineered TILs KSQ-004EX
autologous SOCS1/Regnase-1-edited TILs KSQ-004EX
CRISPR/Cas9-edited SOCS1/Regnase-1 gene-inactivated autologous TILs KSQ-004EX
Regnase-1/SOCS1 dual-edited human CRISPR/Cas9-engineered TILs KSQ-004EX
Code name:KSQ 004
KSQ 004EX
KSQ-004
KSQ-004EX
KSQ004
KSQ004EX
Search NCI's Drug Dictionary